# Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .

Study · id `cardio:ct-nct04707352` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04707352](<https://clinicaltrials.gov/study/NCT04707352>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04707352

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

## Technical summary

Registry record NCT04707352. Allocation not applicable; no masking; primary purpose treatment. Start 2021-02-08 (actual); primary completion 2023-03-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 162 participants (enrolled count; ClinicalTrials.gov record NCT04707352, source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)
- Started: 2021-02-08 (actual) (ClinicalTrials.gov record NCT04707352, source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)
- Primary completion: 2023-03-26 (actual) (ClinicalTrials.gov record NCT04707352, source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)
- Completion: 2023-03-26 (actual) (ClinicalTrials.gov record NCT04707352, source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT04707352, source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04707352-2023-07-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
- Acronym: MODA
- Condition: Heart Failure
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Lead sponsor class: OTHER
- Collaborator: Spanish Society of Cardiology
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as a collaborator: Spanish Society of Cardiology (`cardio:org-spanish-society-of-cardiology`)

## Provenance

Content hash: ff30d006071f7ef2c955616c57dc4b7ef225e6425266cfe2fd8a77c99fe4f8c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
